Product Information
DESOGESTR-ETH ESTRAD ETH ESTRA is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.1610 per EA under NDC 00378729653. Its NADAC has been published 624 times since Sep 10, 2014.
FDA first approved this application on Aug 30, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378729653
Classification
Generic
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA202296FDA Approved
8/30/2013
TE Code
AB
On Market Since
7/16/2014
Price Statistics
The NADAC for DESOGESTR-ETH ESTRAD ETH ESTRA has been published 624 times since Sep 10, 2014, and over the history we have for it it has declined 84.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1610 per EA |
|---|---|
| All-time high | $1.0592 (Dec 10, 2014) |
| All-time low | $0.1319 (Apr 17, 2024) |
| 52-week high | $0.2029 |
| 52-week low | $0.1493 |
| Median price | $0.4454 |
| Average price | $0.4738 |
| Largest weekly change | +42.3% (Nov 22, 2023) |
| Weeks tracked | 624 |
| Tracking since | Sep 10, 2014 |
1W
N/A
1M
N/A
3M
+7.8%
6M
-3.9%
1Y
-18.6%
3Y
-10.6%
5Y
-34.2%
All
-84.2%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the desogestrel and ethinyl estradiol and ethinyl estradiol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
desogestrel and ethinyl estradiol and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DESOGESTR-ETH ESTRAD ETH ESTRA?
The current National Average Drug Acquisition Cost (NADAC) for DESOGESTR-ETH ESTRAD ETH ESTRA, manufactured by Mylan Pharmaceuticals Inc., is $0.1610 per EA (NDC 00378729653), effective Aug 19, 2026.
How has the price of DESOGESTR-ETH ESTRAD ETH ESTRA changed over time?
Over the history we have for it, the NADAC for DESOGESTR-ETH ESTRAD ETH ESTRA has declined 84.2%. It has been tracked across 624 weekly CMS publications since Sep 10, 2014.
What are the highest and lowest recorded NADAC prices for DESOGESTR-ETH ESTRAD ETH ESTRA?
Since Sep 10, 2014, the NADAC for DESOGESTR-ETH ESTRAD ETH ESTRA has ranged from a low of $0.1319 (Apr 17, 2024) to a high of $1.0592 (Dec 10, 2014), with a median of $0.4454 per EA.
Are there cheaper alternatives to DESOGESTR-ETH ESTRAD ETH ESTRA?
No other NADAC-published product currently shares the active ingredient and strength of DESOGESTR-ETH ESTRAD ETH ESTRA in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DESOGESTR-ETH ESTRAD ETH ESTRA?
DESOGESTR-ETH ESTRAD ETH ESTRA (NDC 00378729653) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.